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We  explored  the  hypothesis  that complement,  an innate  and adaptive  immune  effec-
tor,  is active  in the plasma  of  parturient  women  and is deposited  on  fetal  membranes
collected  after  delivery.  A cross-sectional  study  was designed  to  evaluate  comple-
ment  activity  at  parturition.  Pregnant  women  (n = 97)  between  15  and  41  years  of
age  were  enrolled  in  a hospital  protocol  during  the  perinatal  period  to assess  both
SC5b-9  complement  activity  in  blood  and  complement  deposition  on  fetal  mem-
branes  during  parturition.  Soluble  SC5b-9  complement  activity  in  plasma  fractions
was  measured  using  a standard  enzyme-linked  immunosorbent  assay  (ELISA)  that
included  speciﬁc  anti-complement  antibodies.  Complement  deposition  on  membranes
was  analyzed  using  immuno-dot  blots  and  immunohistochemistry.  Soluble  SC5b-9 com-
plement complex  levels  were  increased  in the  plasma  of women  during  term  labor
(TL;  median  3361;  range  1726–5670  ng/mL),  preterm  labor  (PL;  median  2958;  range
1552–7092  ng/mL),  and  preterm  premature  rupture  of membranes  (PPROM;  median  2272;
range  167–6540  ng/mL)  compared  with  pregnant  women  who  were  not  in  labor  (P;
median  1384;  range  174–4570  ng/mL;  P < 0.001,  Kruskal–Wallis  test).  Active  comple-
ment,  as  assessed  by  the C9  neo-antigen  in  C5b-9  complexes,  was  deposited  on fetal
membranes,  with  no  difference  between  term  and  preterm  delivery.  The  deposition  of
active complement  on  fetal  membranes  was  conﬁrmed  by immunohistochemistry.  Women
who  underwent  non-labor-indicated  Cesarean  sections  did  not  exhibit  complement  deposi-
tion. Soluble  SC5b-9  complement  complex  levels  increased  in  the  plasma  of  women  during
parturition,  and  complement  C5b-9  complexes  were  deposited  on fetal  membranes.
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. Introduction
Parturition is a physiological process that requires the
ynchronization of uterine contractions, cervical dilatation,
nd membrane rupture. Several reviews have emphasized
hat the physiological phenomena, molecules, and cellular
echanisms that drive the process of human parturi-
ion are not completely understood (Breuiller-Fouche and
ermain, 2006). The complement system is an important
ffector of the immune system because it forms pores
n cell membranes that lead to cell lysis; thus, the com-
lement system is thought to play a crucial role during
arturition. C4B and C1R protein levels are lower during
pontaneous vaginal delivery (SVD) than during pre-labor
n the same women (Yuan et al., 2012). However, the com-
lement system and its role during parturition have not
een explored as extensively as the cytokines that mediate
he parturition-dependent inﬂammatory response. New
echniques, including standard enzyme-linked immunoab-
orbent assay (ELISA), now permit the evaluation of
omplement activity with improved sensitivity. Different
ethodological approaches have been used to determine
omplement activity in biological ﬂuids, such as those used
o assess the protein complex C5b-9 in plasma. This protein
omplex is a common mediator of cell lysis that is gener-
ted from any of the four complement activation pathways
Huber-Lang et al., 2006). The regulatory S protein binds
o C5b-9, forming the SC5b-9 complex, which is soluble
nd can be detected in plasma by ELISA (Mollnes et al.,
985).
We  hypothesized that the complement system is active
t parturition during established labor. This study aimed to
nvestigate whether the active form of complement, C5b-9,
s elevated in plasma as SC5b-9 at parturition and whether
omplement is deposited on fetal membranes.
. Materials and methods
.1. Study design
To understand complement activity at parturition, a
ross-sectional study was designed to assess complement
ctivity in the plasma and complement deposition on fetal
embranes. Pregnant women (n = 97) between 15 and
1 years of age who were treated as outpatients from 12
eeks of gestation until delivery at the National Institute of
erinatology (INPer, Mexico City, Mexico) were recruited
or the study. Patients with cancer and patients receiving
mmunotherapy for transplants or autoimmunity or cur-
ent steroid treatment were excluded from the study. The
atients provided written informed consent during their
linical check-ups. Each patient consented to donate four
etal membrane samples (1 cm in diameter) after child-
irth. Furthermore, one 3-mL sample of whole peripheral
lood was obtained from each patient at delivery or during
ormal examinations as stated in Section 3. The study
articipants included pregnant women (P) at <37 weeks
f gestational age. Sample membranes were also isolated
rom women undergoing an indicated Cesarean section at
36 weeks. Women  at >37 weeks of gestational age com-
rised the term labor (TL) group, and women at <37 weeksctive Immunology 109 (2015) 24–30 25
of gestational age were assigned to one of two  subgroups:
the preterm labor (PL) or preterm premature rupture of
membranes (PPROM) group. A ﬂow diagram is presented
in Fig. 1. The study participants were at minimal risk. The
study was approved by the research and bioethical com-
mittees of the National Institute of Perinatology and was
in compliance with international guidelines for human
studies.
2.2. SC5b-9 protein complex assessment
The C5b-9 complex binds the regulatory S protein
after the C5b-7 protein complex is properly assembled
in the plasma (Mollnes et al., 1985; Bhakdi and Tranum-
Iensen, 1982). SC5b-9 complex levels in the plasma are
indicative of complement activation, which causes sub-
sequent cell lysis. SC5b-9 complex levels were analyzed
using a standard ELISA assay (Quidel, Mountain View,
CA, USA) as previously reported (Walter et al., 2010).
Participant plasma samples were routinely diluted 1:40.
The samples were assayed in triplicate wells (100 L)
and were incubated for 60 min  according to the manu-
facturer’s instructions. The method was quantitative for
SC5b-9 complex levels ranging from 20 to 150 ng/mL.
The color was developed by incubating the samples
with 100 L/well of the chromogenic substrate OPD
(O-phenylenediamine dihydrochloride, Sigma-Aldrich, St.
Louis, MO,  USA) for 30 min  at room temperature. The
plates were read using an automated ELISA plate reader
(Synergy 2, Bio-Tek Instruments, Winooski, VT, USA) after
the enzyme reaction was  terminated by the addition of
50 L of 0.1 M H2SO4. The absorbance was  measured at
405 nm.
2.3. Fetal membrane sampling
We  investigated whether active complement was
deposited on fetal membranes (1 cm in diameter), includ-
ing the chorion and amnion. The fetal membranes were
obtained within the ﬁrst 30 min  after childbirth and were
assessed in duplicate at four points from the rupture site
following a previously published protocol (McLaren et al.,
1999)Ref. . One membrane sample from each duplicate was
incubated in phosphate-buffered saline (PBS; pH 7.4) con-
taining a mammalian protease inhibitor cocktail (PIC, 1:50
dilution; Sigma-Aldrich, St. Louis, MO,  USA). The samples
were frozen at −70 ◦C and stored until they were used in
standard immuno-dot blot assays (Janyapoon et al., 2000)
of membrane complement components. The other mem-
brane samples were used for the immunohistochemical
detection of complement components.
2.4. Protein membrane extraction and immuno-dot blot
assay
Complement components were detected in protein
fractions extracted from fetal membranes. Brieﬂy, the
membrane tissue was mechanically disrupted in a tissue
grinder with 3 mL of cold PBS containing a protease
inhibitor cocktail (PBS-PIC). The suspended cells were
recovered and centrifuged at 400 × g. The cell pellet was
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f the paFig. 1. A ﬂow diagram o
disrupted by several freeze–thaw cycles. The suspended
fraction was transferred to an Eppendorf tube and cen-
trifuged at 20,000 × g for 20 min. The collected supernatant
was discarded, and the pellet was re-suspended in 200 L
of PBS-PIC with 1% Nonidet P-40 (a non-ionic detergent
used to extract proteins from cell membranes, Sigma-
Aldrich, St. Louis, MO,  USA). The protein samples were
re-centrifuged at 20,000 × g for 30 min. Then, 1 L of the
supernatant was directly applied to a polyvinylidene diﬂu-
oride membrane in triplicate (0.45-m PVDF membranes,
Bio-Rad Labs, Hercules, CA, USA). Non-speciﬁc binding
sites were blocked for 1 h in PBS (pH 7.4) containing 5%
low-fat milk. The membranes were incubated overnight
at 4 ◦C with a 1:50 dilution of an HRP-conjugated anti-C9
neo-antigen monoclonal antibody (Quidel, Mountain
View, CA, USA). The monoclonal antibodies used to detect
the complement components in this assay were labeled
with horseradish peroxidase (HRP; Sigma-Aldrich, St.
Louis, MO,  USA) in our laboratory according to a standard
procedure (Harlow and Lane, 1988). The membranes
were washed three times (5 min  each) with PBS (pH
7.4)/0.05% Tween-20 to remove excess unbound antibody.
The peroxidase-positive dots were detected by immersing
the membrane in a developing solution (70 mM sodium
acetate at pH 6.2 containing 0.3% diaminobenzidine
tetrahydrochloride and 0.03% H2O2) at room temperature
for 5 min. The enzymatic reaction was terminated by
washing the sheet. The immunoreactive protein signals
were detected using an AlphaImager HP System (Cell
Biosciences, Inc., Santa Clara, CA, USA).tient selection process.
2.5. Immunohistochemistry
The presence of the C9 neo-antigen from active com-
plement was  analyzed in formalin-ﬁxed, embedded tissue
sections using the previously described HRP-conjugated
mAbs (anti-C9 neo-antigen; Quidel, Mountain View, CA,
USA). Brieﬂy, fetal membranes were ﬁxed in 4% formalin
(Sigma-Aldrich, St. Louis, MO,  USA), and 4-m-thick sec-
tions were mounted on parafﬁn slides. The parafﬁn was
removed, and the sections were rehydrated with PBS (pH
7.4) for 30 min  at room temperature. The tissue sections
were then covered with 3% hydrogen peroxide to block
endogenous peroxidase activity. A previously described
standard procedure was  used for tissue staining (Ratnoff
et al., 1995).
2.6. Statistical analysis
The clinical characteristics of the participants are pre-
sented using descriptive statistics, the mean ± standard
deviation for continuous variables, and proportions and
percentages for qualitative variables. One-way analysis
of variance (ANOVA) was initially performed. When the
Levine test for the equality of variances indicated signif-
icant differences, the Kruskal–Wallis test was used. The
proportions were compared using Fisher’s exact test for
expected values less than ﬁve. A P value <0.05 was  con-
sidered statistically signiﬁcant. Statistical analyses were
performed using XL-STAT 2013, version 5.06 for Windows
(Addinsoft, New York, NY, USA).
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. Results
.1. Patient characteristics
The clinical parameters of the patients recruited into the
tudy are provided in Table 1. No signiﬁcant differences
ere noted between the pregnant and parturient groups
egarding maternal age or the incidence of diabetes, uter-
ne myomas, anemia or preeclampsia. The gestational age
nd the prevalence of urinary tract infections, chorioam-
ionitis, and cervicovaginal infections varied between the
roups.
.2. Detection of SC5b-9 in plasma
To analyze complement activity in pregnant women,
e determined the plasma levels of the soluble SC5b-9
omplex in parturient women at different gestational ages
nd conditions as described above (TL, PL, and PPROM;
 = 59). For comparison purposes, pregnant women (P,
 = 38) at <37 weeks of gestational age who exhib-
ted no signs of parturition were also studied. The
edian estimated concentration of the soluble SC5b-9
omplex in parturient women was 3361 ng/mL for the
L group (range 1726–5670 ng/mL; n = 8), 2958 ng/mL
or the PL group (range 1552–7092 ng/mL; n = 25),
272 ng/mL for the PPROM group (range 167–6540 ng/mL;
 = 26), and 1384 ng/mL for the control P group (range
74–4570 ng/mL; n = 38; P < 0.001, Kruskal–Wallis test;
ig. 2).
.3. Immuno-dot blot assays
We  analyzed neo-antigen C9, which is expressed when
he C5b-9 complex forms, to determine whether active
omplement was deposited on fetal membranes. Neo-
ntigen C9 from active complement was studied in protein
xtracts from fetal tissue membranes from women in
he TL (n = 6), PL (n = 10), and PPROM (n = 12) groups
t delivery. The group of pregnant women (P) was not
ncluded in this analysis because they had not yet given
irth. The tissues were analyzed using standard immuno-
ot blot assays as previously described in Section 2. An
able 1
linical Characteristics of study participants.
Group Pregnant (P)
n  = 38
Term Labor (TL) n = 8
(>37 weeks)
Pr
n  =
Mother age (years)* 28 ± 6.8 28 ± 6.2 28
Gestation age (weeks)* 24.6 ± 8.8 39 ± 1.4 33
Gestational diabetes** 2/38 2/8 3/
Urinary tract infection** 1/38 1/8 7/
Chorioamnionitis** 0/38 0/8 4/
Cervicovaginal infection** 0/38 0/8 3/
Uterine myomas** 3/38 2/8 0/
Anemia** 1/38 1/8 2/
Preeclampsia** 3/38 0/8 4/
a ANOVA test.
b Kruskal Wallis test.
c Fisher’s exact test.
* Values expressed as median ± standard deviation.
** Frequency (percentage).ctive Immunology 109 (2015) 24–30 27
intense C9 neo-antigen stain was  evident on the mem-
branes from all the groups, indicating that complement was
deposited on the fetal membranes (Fig. 3A). Variable C9
neo-antigen deposits were noted in all the groups based
on color intensity, which was measured by densitometry
(Fig. 3B). The respective mean ± standard deviation val-
ues for the TL, PL, and PPROM groups were 5885 ± 536,
5918 ± 1040, and 6252 ± 1083 respectively at point a
(P > 0.05, ANOVA); 5614 ± 250, 5443 ± 200, and 5780 ± 703
at point b (P > 0.05, ANOVA); 6862 ± 1418, 5875 ± 1064,
and 5631 ± 408 at point c (P > 0.05, Kruskal–Wallis test);
and 7288 ± 1487, 5748 ± 886, and 5814 ± 692 at point
d (P > 0.05, Kruskal–Wallis test). The lack of differences
between these values suggested that term or preterm
fetal membranes exhibited complement deposition at
birth regardless of the length of the pregnancy. Negative
immuno-dot blot assays were observed for samples from
women who  were not in labor or who were delivering by
Cesarean section.
3.4. Immunohistochemistry
The conﬁrmation of complement component deposits
on fetal membranes was crucial for understanding their
role in parturition. Selected sections from each group
are presented in Fig. 4 for comparison purposes. Active
complement deposits were not detected in anti-C9 neo-
antigen-stained fetal membranes from preterm women
who delivered by Cesarean section (n = 2; Fig. 4A).
C9 neo-antigen deposits were observed in the external
membrane of the amniotic epithelium, the amniotic base-
ment membrane, and the compact layer of the connective
tissue of fetal membranes obtained from term women who
underwent labor (Fig. 4B). Apoptotic cells were noted in the
membrane samples from the TL group (n = 2). Thus, apop-
totic nuclei were detected in the at-term membranes, but
not in the preterm tissue (data not shown).
The immunostaining pattern during preterm labor indi-
cated strong staining in the cytoplasm of cells from the
trophoblast layer (Fig. 4C, n = 3). In the ﬁbroblast layer of
the connective tissue from participants in the PPROM group
(n = 4), up to 5% of the cells exhibited cytoplasmic anti-C9
neo-antigen staining (Fig. 4D).
eterm labor (PL)
 25 (<37 weeks)
Premature Rupture of Membranes
(PPROM) n = 26 (<37 weeks)
P
.3 ± 7.5 24.5 ± 7.1 >0.05a
 ± 2.5 33 ± 2.4 0.00b
25 3/26 0.15c
25 7/26 0.01c
25 3/26 0.04c
25 5/26 0.02c
25 5/26 0.06c
25 1/26 0.47c
25 2/26 0.66c
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Fig. 2. Plasma SC5b-9 values based on gestational resolution. Values are presented for pregnant women  between 26 and 37 weeks of gestation and for the
three  groups of women  with resolved pregnancies: TL (term labor), PL (preterm labor), and PPROM (preterm premature rupture of membranes). The values
are  presented as the median (the line across the middle of the box) and the 75th and 25th percentiles (the upper and lower ends of the box; P < 0.001;
Kruskal–Wallis test).
Fig. 3. Immuno-dot blot of fetal membranes using the anti-C9 neo-antigen. Membranes from patients who  underwent different types of deliveries exhibited
active  complement deposits (A). Points (a) and (d) are equidistant from the fetal membrane rupture site. In (B), the mean ± standard deviation of the dot
color  intensity was  determined using myImage Software V2.0 (Thermo Scientiﬁc), and data are presented for each point (a–d) for each group: term labor
(TL),  preterm labor (PL) and preterm premature rupture of membranes (PPROM; P > 0.05, ANOVA for points a and b and Kruskal–Wallis test for points c
and  d).
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Fig. 4. Fetal membranes with complement deposition. Selected sections from each group are presented for comparison purposes. (A) Fetal membrane
fragments from an indicated preterm pregnancy delivered by Cesarean section did not exhibit complement deposition; (B) a sample from a term labor patient
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. Discussion
The evidence described herein suggests that comple-
ent might be active during parturition and deposited on
etal membranes. Complement may  cooperate with matrix
etalloproteinases (Athayde et al., 1998; Lei et al., 1996)
nd apoptosis (Lei et al., 1996; Murtha et al., 2002) to
eaken the membranes and facilitate the onset of labor.
he results are consistent with those of previous studies,
emonstrating that complement is active at parturition.
he present study demonstrated the immunohistochem-
cal localization of the C9 neo-antigen, which emerges only
fter complement is activated.
The identiﬁcation of increased complement activity in
he plasma at the end of pregnancy, as demonstrated
y increased SC5b-9 levels in plasma, could be used as
n indicator of the delivery period for either preterm or
erm pregnancies. Moreover, because complement activ-
ty is modulated by endogenous regulators (e.g., decay
ccelerating factor (DAF/CD55) and membrane cofactor
rotein (MCP/CD46), anticomplement therapy could be uti-
ized to extend pregnancy in women undergoing preterm
abor. Complement inhibition therapy has been assessed
n myocardial infarction (Doran et al., 1996; Hyde et al.,
998; Monsinjon et al., 2001), cerebral stroke (Huang et al.,
999), and anti-phospholipid antibody syndrome (Holers
t al., 2002). These studies demonstrated positive effects
egarding reduced tissue damage and improved functional
ecovery. In fact, anticomplement therapy has so many
pplications that several drugs are now under develop-
ent in both preclinical and clinical trials. Based on the
echanism of action, anticomplement drugs have beennti-C9-neo-antigen antibody indicated intense complement deposition;
(400× magniﬁcation).
classiﬁed into ﬁve groups: serine protease inhibitors (C1-
INH, Rhucin/rhC1INH), therapeutic antibodies (eculizumab
and pexelizumab: C5; and ofatumumab: anti-CD20), solu-
ble complement regulators (sCR1/TP10: extracellular part
of CR1, decay accelerator, and factor I cofactor; and
CAB-2/MLN-2222: chimera of DAF and MCP), comple-
ment component inhibitors (compstatin/POT-4: peptidic
C3 inhibitor), and receptor antagonists (PMX-53: peptidic
C5aR antagonist). The last three groups comprise more
promising molecules because of their molecular character-
istics as small molecules with high potency and selectivity
(Kulkarni and Afshar-Kharghan, 2008; Ricklin and Lambris,
2013).
In the present study, the amount of SC5b-9 was mea-
sured regardless of the pathway by which the complement
system was  activated (classical, alternative, lectin, or
extrinsic). Therefore, the values reported by other studies
in women during preterm delivery and not during term
delivery with spontaneous labor may  differ from our data
because those studies focused on the complement frag-
ment Bb. The Bb protein is activated via the alternative
complement pathway (Vaisbuch et al., 2010; Lynch et al.,
2008).
Historically, early studies on the classical activation
pathway revealed that C3 and C4 had no predictive
value in the timing of normal labor when assayed using
radial immunodiffusion (Kovar and Riches, 1988). Subse-
quently, C3a, C4a, and C5a (products of active complement)
were measured by immunoassay during pregnancy, and
increased levels of these products were observed in
pregnant women compared with non-pregnant women
(Richani et al., 2005). More recently, mannose-binding
Reprodu30 E. Segura-Cervantes et al. / Journal of 
lectin (MBL) pathway activity was discovered, and this
pathway was investigated by ELISA during pregnancy in
a longitudinal study. This study found that MBL  concentra-
tions increase during pregnancy and decrease postpartum
(Van de Geijn et al., 2007). Furthermore, the C4d, C3a, SC5b-
9, C3, C9, and factor H levels were signiﬁcantly higher in
healthy pregnant women than in non-pregnant women.
Conversely, C1 inhibitor levels were signiﬁcantly lower
in healthy pregnant women compared with non-pregnant
women (Derzsy et al., 2010).
These studies indicate that the complement system is
active during normal pregnancy. Active complement facil-
itates the remodeling and generation of maternal tissue to
promote fetal growth and allows the fetus to adapt to the
increasing demand for space during pregnancy. Multiple
studies have indicated that the role of the complement sys-
tem during tissue remodeling involves binding apoptotic
cells via enhanced opsonization and eliciting their subse-
quent removal through phagocytosis (Girardi et al., 2006;
Read et al., 2007; Runic et al., 1998). Tissue remodeling is
associated with apoptosis (Murtha et al., 2002) and is a
common event that promotes the activation of the com-
plement cascade to facilitate the deposition of the C5b-9
complex in the placenta, decidua, and fetal membranes.
Our study revealed that the C5b-9 protein complex is pri-
marily deposited in the amnion.
In conclusion, our study showed that women exhibit
increased SC5b-9 plasma levels and C9 neo-antigen deposi-
tion on fetal membranes during parturition. This deposition
is indicative of complement activity during parturition.
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